Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation

PHASE4CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

May 28, 2021

Primary Completion Date

February 8, 2023

Study Completion Date

June 30, 2023

Conditions
Acne Vulgaris
Interventions
DRUG

Trifarotene Cream

Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream to the face once daily, in the evening for 24 weeks

DRUG

Trifarotene Vehicle Cream

Participants will apply a thin a layer of trifarotene vehicle cream to the face once daily, in the evening for 24 weeks

Trial Locations (18)

11790

Galderma Investigational Site #8881, Stony Brook

18249

Galderma Investigational Site #8886, Sugarloaf

30078

Galderma Investigational Site #8189, Snellville

33027

Galderma Investigational Site #8883, Miramar

33136

Galderma Investigational Site #8295, Miami

33437

Galderma Investigational Site #9928, Boynton Beach

44093

Galderma Investigational Site #6167, Nantes

60005

Galderma Investigational Site #8367, Arlington Heights

60561

Galderma Investigational Site #8838, Darien

70001

Galderma Investigational Site #8601, Metairie

70130

Galderma Investigational Site #9936, New Orleans

72916

Galderma Investigational Site #8447, Fort Smith

76011

Galderma Investigational Site #9920, Arlington

85260

Galderma Investigational Site #8873, Scottsdale

89148

Galderma Investigational Site #8108, Las Vegas

90404

Galderma Investigational Site #8608, Santa Monica

Unknown

Galderma Investigational Site #9918, Peterborough

Galderma Investigational Site #9927, Saint-Jérôme

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Galderma R&D

INDUSTRY

NCT04856904 - Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation | Biotech Hunter | Biotech Hunter